Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 211, Issue 6, Pages 1049-1062Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20131751
Keywords
-
Categories
Funding
- Thome Memorial Medical Foundation
- Alzheimer's Drug Discovery Foundation
- National Institutes of Health [NS50537]
- Woodbourne Foundation
- Mellam Family Foundation
- May and Samuel Rudin Family Foundation
- Blanchette Hooker Rockefeller Fund
Ask authors/readers for more resources
Many Alzheimer's disease (AD) patients suffer from cerebrovascular abnormalities such as altered cerebral blood flow and cerebral microinfarcts. Recently, fibrinogen has been identified as a strong cerebrovascular risk factor in AD, as it specifically binds to beta-amyloid (A.), thereby altering fibrin clot structure and delaying clot degradation. To determine if the A beta-fibrinogen interaction could be targeted as a potential new treatment for AD, we designed a high-throughput screen and identified RU-505 as an effective inhibitor of the A beta-fibrinogen interaction. RU-505 restored A beta-induced altered fibrin clot formation and degradation in vitro and inhibited vessel occlusion in AD transgenic mice. Furthermore, long-term treatment of RU-505 significantly reduced vascular amyloid deposition and microgliosis in the cortex and improved cognitive impairment in mouse models of AD. Our studies suggest that inhibitors targeting the A beta-fibrinogen interaction show promise as therapy for treating AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available